Evidence map›Paper›PMID 33039370›Full record

ArticleHuman pathology2021

Biopsies of hepatocellular carcinoma with no reticulin loss: an important diagnostic pitfall.

Saba Yasir, Zongming Eric Chen, Samar Said, Tsung-Teh Wu, Michael Torbenson

Open access · greenAbstract read
In one paragraph

Article in Human pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Saba YasirDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA.
Zongming Eric ChenDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA.
Samar SaidDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA.
Tsung-Teh WuDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA.
Michael TorbensonDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA. Electronic address: Torbenson.Michael@mayo.edu.
Mayo Clinic in Arizona · US

Funding

Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Rory Smoot · 2018 to 2026
$20.5M
NCI NIH HHS P50 CA210964
6 · The paper itself

Abstract

The reticulin stain is a critical diagnostic aide used to differentiate benign hepatocellular proliferations from well differentiated hepatocellular carcinoma (HCC). Rarely, however, hepatocellular carcinomas do not show definitive loss of reticulin in liver biopsy specimens. To study this group of tumors, 11 HCC with no reticulin loss in 10 patients were collected and studied. Analysis of demographics showed a typical enrichment for men with a typical age for HCC presentation of 69 ± 7 years for adults. The background livers showed advanced fibrosis or cirrhosis in 6 of 6 cases with available information. The tumors were all well differentiated. Cytological atypia was mild and consisted of very mild nuclear atypia (8 cases), mild increase in N:C ratio (3 cases), and pseudorosette formation (4 cases). The cytological/architectural atypia was insufficient in isolation to diagnose HCC. Additional studies, however, showed an increased Ki-67 proliferative rate (N = 10/10 stained cases). The Ki-67 proliferative rate was estimated to be between 5 and 10% in all tested cases and was clearly increased from adjacent liver at low power. Glypican 3 positivity (4 tumors) and alpha fetoprotein (AFP) (1/8 stained cases) positivity also helped make the diagnosis of HCC. Morphologically, the HCC had conventional morphology with five showing steatosis/steatohepatitic features and one showing intratumoral fibrosis. A control group of macroregenerative/dysplastic nodules showed no increase in Ki-67 proliferation and no staining for glypican 3. These findings highlight an important diagnostic pitfall: rare HCC show no reticulin loss on biopsy. In these challenging cases, additional findings are useful to make a diagnosis of HCC: increased Ki-67 and positive staining for aberrant expression of proteins such as glypican 3 or AFP.

Indexed as

AdultAgedBiomarkers, TumorBiopsyCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedReticulinBiomarkers, TumorReticulinAFPBeta-cateninGlypican 3Hepatocellular carcinomaKi-67Reticulin

Identifiers

PMID33039370
PMCPMC9177079
OpenAlexW3092043859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.